IMC Chicago’s BioMarin Pharmaceuticals BMRN Stock Holding History

IMC Chicago’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$542K	Buy	9,467 +3,867	+69%	+$212K	﹤0.01%	4551
2026 Q1	$316K	Buy	+5,600	New	+$327K	﹤0.01%	4534
2025 Q3	–	Sell	-11,866	Closed	-$679K	–	3616
2025 Q2	$652K	Buy	+11,866	New	+$699K	﹤0.01%	2728
2022 Q1	–	Sell	-17,576	Closed	-$1.55M	–	1092
2021 Q4	$1.55M	Buy	+17,576	New	+$1.45M	﹤0.01%	882
2021 Q2	–	Sell	-24,121	Closed	-$1.91M	–	1103
2021 Q1	$1.82M	Buy	+24,121	New	+$1.97M	﹤0.01%	753
2019 Q1	–	Sell	-2,892	Closed	-$246K	–	653
2018 Q4	$246K	Buy	+2,892	New	+$275K	﹤0.01%	800

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

AIM

ARGA Investment Management Stamford, Connecticut $3.92B AUM 35.93% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

FWIA

Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

IMC Chicago's BMRN Position: Q2 2026 in Review

IMC Chicago increased its BioMarin Pharmaceuticals (BMRN) stake by 69% in Q2 2026, buying an estimated $212K and bringing the position to 9,467 shares worth $542K. The position accounts for ﹤0.01% of the portfolio, ranked #4551.

IMC Chicago first reported a position in BMRN in Q4 2018 and has held it in 6 quarters since. The position peaked at $1.82M in Q1 2021. 261 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

IMC Chicago held 9,467 shares of BioMarin Pharmaceuticals worth $542K as of Q2 2026.
IMC Chicago bought 3,867 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $212K.
BioMarin Pharmaceuticals made up ﹤0.01% of IMC Chicago's portfolio in Q2 2026, its #4551 holding.
IMC Chicago first reported a position in BioMarin Pharmaceuticals in Q4 2018 and has held it in 6 quarters since.
IMC Chicago's BioMarin Pharmaceuticals position peaked at $1.82M in Q1 2021.
261 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on IMC Chicago's 13F filing for Q2 2026, filed 6 Aug 2026.